Simplify Logo

Full-Time

Director – New Product Planning

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Healthcare
Biotechnology

Senior, Expert

Cambridge, MA, USA

70/30 work model; 70% in-office presence required.

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • 8+ years of experience working for a clinical- or commercial-stage pharmaceutical/biotech company in strategy or new product planning
  • MBA or PhD preferred, with an understanding of drug development and value creation in the biopharmaceutical industry, and commitment to learn about the science behind our platform technology
Responsibilities
  • Act as a strategic thought partner for early clinical-stage program teams, providing insights and guidance to ensure informed decision-making at the program level
  • Develop a deep understanding of market dynamics, competitive landscapes, patient needs, and target biology to lead the generation and analysis of required evidence to support product value and differentiation
  • Drive primary and secondary market research and engage with external experts, KOLs, and advisory boards to distill market trends, assess unmet needs, and gather insights on customer behavior
  • Oversee the creation, refinement and evolution of Target Product Profiles (TPPs), ensuring alignment with program strategic objectives and market needs
  • Lead generation of program and market assumptions for market sizing and revenue forecasting
  • Craft compelling value propositions that resonate with stakeholders and support market access strategies
  • Collaborate closely with Research, Development, Commercial, Finance, CMC and additional functions maximize the value of the program for patients and our platform

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

8%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.